ACR 2022 Tweet by David Liew
Tweet
Related Content
Intra-Articular Injections for Knee OA: Options, Evidence, and no Clear Winner
Jiha Lee, MD
Nov 2, 2026
At APLAR 2026 in Seoul, the OA special interest group offered a whirlwind overview of IA injectables from Dr. Gun-il Im (Dongguk University, Korea). The products fall into three tiers: symptom-modifying, biologic/regenerative and structure-oriented. The pipeline is encouraging, but the evidence is uneven and often thin.
UBER Rheumatology Ride (3.6.2026)
Jack Cush, MD
Mar 6, 2026
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.comCross-sectional study of Joint hypermobility (JH) in 256 young adults (75% female) found JH in 42%, females w/ signif. higher Beighton scores. 88% had chronic MSK pain; 38% had acute MSK pain. MSK pain was signif…
A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to placebo).


